Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT00002354 · ClinicalTrials.gov registry record · NA
A Study of Indinavir Sulfate Given Together With Stavudine to HIV-Positive Patients
A NA study, sponsored by Merck Sharp & Dohme.
- Completed
- Registry status
- NA
- Development phase
- 540
- Enrollment target
NCT00002354: Completed NA study, sponsored by Merck Sharp & Dohme.
NCT00002354 is a NA study that has completed, run by Merck Sharp & Dohme. The registered enrollment target is 540 participants, below the 1,404-participant average among 58,714 other NA trials with a reported enrollment target (62% lower). According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT00002354, a NA study, has completed, sponsored by Merck Sharp & Dohme.
- COMPLETED
- Registry status
- NA
- Development phase
- 540 participants
- Enrollment target
Study Summary
The purpose of this study is to see if it is safe and effective to give indinavir sulfate plus stavudine to HIV-infected patients who have already been treated with zidovudine.
Interventions
- DRUG Indinavir sulfate
- DRUG Stavudine
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 540 participants |
| Phase | NA |
What the finished NCT00002354 record still lists
NCT00002354 is an interventional study that assigns participants to a tested intervention. The registered 540 participants enrollment target is mid-sized for trials with a published cap, below the 1,404-participant average among 58,714 other NA trials with a reported enrollment target (62% lower).
The record links to 0 conditions, and to 2 interventions - of which Indinavir sulfate is the first listed.
NCT00002354 does not publish any study locations in the registry export this page uses.
Frequently Asked Questions
What is clinical trial NCT00002354 about?
NCT00002354 is a clinical study titled "A Study of Indinavir Sulfate Given Together With Stavudine to HIV-Positive Patients". The purpose of this study is to see if it is safe and effective to give indinavir sulfate plus stavudine to HIV-infected patients who have already been treated with zidovudine.
What is the current status of trial NCT00002354?
This trial is currently completed. It is a NA study. The enrollment target is 540 participants.
What interventions are being tested in trial NCT00002354?
The interventions under investigation include: Indinavir sulfate (DRUG), Stavudine (DRUG).
Who is sponsoring clinical trial NCT00002354?
This trial is sponsored by Merck Sharp & Dohme, which has 558 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
How this trial's enrollment target compares
Where NCT00002354's enrollment target sits among peer trials
540 187th of 2000 higher than 1,813 of 2,000 other NA trials
participants (enrollment target), bucketed by value
Each bar is a band; taller bars hold more other NA trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.
Source ClinicalTrials.gov registry export · 2026-08-08
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar enrollment target
- NCT04557462 · 540 participants · Phase 3
A Rollover Extension Program (REP) to Evaluate the Long-term Safety and Tolerability of Open Label Iptacopan/LNP023 in Participants With Primary IgA Nephropathy
- NCT04956640 · 540 participants · Phase 1
Study of LY3537982 in Cancer Patients With a Specific Genetic Mutation (KRAS G12C)
- NCT05429892 · 540 participants · NA
FRESH Delivers: An Innovative Approach to Reducing Tobacco Use Among Rural Smokers
- NCT05549297 · 540 participants · Phase 3
Tebentafusp Regimen Versus Investigator's Choice in Previously Treated Advanced Melanoma (TEBE-AM)